Sangamo Therapeutics updates pipeline strategy, shares trade on Nasdaq

Sangamo Therapeutics focuses on gene regulation and cell therapy programs while its shares continue to trade on the Nasdaq. The rare-disease specialist positions its partnered and wholly owned pipeline for potential future milestones in gene therapy and neurology.

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-26, 21:16.

Sangamo Therapeutics (US79366N1028) develops genomic therapies targeting rare diseases and neurological indications while its stock remains listed on the Nasdaq in New York. The company continues to emphasize gene regulation and cell therapy programs in recent investor and regulatory filings.

Focus on gene regulation platform

Sangamo Therapeutics centers its research on zinc finger protein technology to regulate gene expression, aiming at indications such as Fabry disease and neurology, according to its latest corporate materials. Recent public updates highlight a strategic focus on partnered and wholly owned programs in these areas. Sangamo investor information on its pipeline

The company positions itself in the gene therapy and gene regulation field alongside peers such as CRISPR Therapeutics and Bluebird Bio, all of which also trade on US exchanges like Nasdaq or Nasdaq Global Select. Sangamo continues to reference potential milestones from collaborations and internal programs in its public communications to investors.

Analyst and market context for the shares

Analyst coverage of specialized genomic therapy developers like Sangamo Therapeutics often emphasizes clinical trial progress, partnership milestones and available cash runway as key valuation drivers. Market commentary from US biotechnology research notes that companies in this segment can face significant share-price sensitivity around trial readouts and regulatory decisions. Reuters analysis on gene therapy developers

For Nasdaq-listed biotechnology stocks comparable to Sangamo Therapeutics, research providers such as Goldman Sachs, JPMorgan and Morgan Stanley typically track cash positions, quarterly operating losses and upcoming catalysts when forming ratings. Consensus data platforms compiling these analyst views often show a range of recommendations from Sell to Buy for clinical-stage gene therapy companies with limited approved products but multiple early- and mid-stage trials.

The product behind the stock

Sangamo Therapeutics generates its potential future revenue from genomic medicine candidates, primarily in gene regulation and cell therapy, using proprietary zinc finger protein technology and related platforms. These programs target specific genetic drivers of disease in rare disorders and neurological indications.

Where the stock trades today

Sangamo Therapeutics shares trade on the Nasdaq in the United States; the latest available data from Nasdaq shows the stock quoted in US dollars during regular US trading hours.

Sangamo Therapeutics at a glance

• Company: Sangamo Therapeutics Inc.
• ISIN: US79366N1028
• WKN: 602079
• Ticker: SGMO
• Trading venue: Nasdaq
• Price (as of 2026-06-26, 19:10): data in US dollars on Nasdaq
• Market cap: data in US dollars based on latest Nasdaq figures (as of 2026-06-26)
• Sector / industry: Biotechnology - genomic therapies
• Index membership: not a member of major headline indices such as S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.